Portage Biotech Announces Promising Preclinical Results for PORT-7 in Mesothelioma

Story Highlights
Portage Biotech Announces Promising Preclinical Results for PORT-7 in Mesothelioma

An announcement from Portage Biotech Inc ( (PRTG) ) is now available.

On March 27, 2025, Portage Biotech Inc. announced promising preclinical results for their drug PORT-7, a selective Adenosine A2B receptor inhibitor, in treating mesothelioma. The data, presented at the 2025 European Lung Cancer Congress, showed significant tumor growth inhibition when PORT-7 was used alone or in combination with an anti-PD1 antibody in a murine model. This development supports the initiation of a first-in-human trial for PORT-7. Additionally, Portage is advancing the dose escalation of PORT-6, with plans to combine PORT-6 and PORT-7 for a comprehensive immunotherapy approach in the ADPORT-601 trial, aiming to neutralize adenosine-mediated immune suppression and enhance anti-tumor responses.

More about Portage Biotech Inc

Portage Biotech Inc. is a clinical-stage immuno-oncology company focused on developing a pipeline of novel biologics to enhance the immune system’s ability to combat cancer.

YTD Price Performance: -6.97%

Average Trading Volume: 63,570

Technical Sentiment Signal: Strong Buy

Current Market Cap: $5.09M

Learn more about PRTG stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App